The Justice Department's decision to move medical cannabis from Schedule I to Schedule III under the Controlled Substances Act is the most significant shift in federal drug policy in decades - and for cannabis operators, the most immediate consequence isn't about legality. It's about taxes. For the first time, medical cannabis businesses stand to claim standard federal tax deductions that have been blocked for years, a change with real implications for dispensary economics, capital access, and how multi-state operators structure their businesses going forward.
The 280E Problem, and Why This Changes the Math
To understand why rescheduling matters to any operator running a licensed dispensary, start with Section 280E of the Internal Revenue Code. Because cannabis has been federally classified as a Schedule I controlled substance, cannabis businesses have been barred from deducting ordinary business expenses - payroll, rent, marketing, compliance software, POS systems - from their federal taxable income. That's not a minor inconvenience. It has pushed effective tax rates for cannabis operators well above those of comparable retail businesses, draining capital that would otherwise go toward expansion, staffing, or improved compliance infrastructure.
Moving medical cannabis to Schedule III removes that barrier for the medical side of the business. As Trulieve Cannabis Corp.'s executive director of government relations put it plainly: operators can now be treated and taxed like a normal business, which ultimately helps the bottom line and allows for more meaningful reinvestment in operating states. For a large multi-state operator running dozens of dispensaries with medical licenses, that shift is material. For a small single-state medical dispensary already operating on thin margins, it may be the difference between staying solvent and not.
Here's the catch, though: the IRS and Treasury Department have not yet issued formal guidance on how the change applies in practice. Until that guidance arrives, operators face a planning gap. They know the rule is changing. They don't yet know exactly how to apply it on a tax return.
Two Legal Frameworks for the Same Product on the Same Shelf
What makes this particularly complicated for dispensary operators is the dual-market problem. In the 24 states and the District of Columbia that allow adult-use cannabis - plus the many additional states with medical-only programs - a significant portion of licensees hold both medical and recreational authorizations. Recreational cannabis remains Schedule I under federal policy. That means a single operator, potentially serving patients and adult-use consumers from the same retail floor, now operates under two distinct federal classifications for what is, in many cases, the same product in the same SKU inventory.
California's Department of Cannabis Control moved quickly, proposing emergency regulations in mid-May that would let dual-license holders obtain separate medical and recreational licenses. The practical intent is clear: position businesses to capture whatever tax and compliance benefits attach to the medical classification while keeping the adult-use side structurally separate. Whether other states follow California's approach or wait for federal guidance is an open question.
Nevada offers a different posture. State cannabis officials acknowledged that the rescheduling allows medical licensees to register with the DEA - but also emphasized that Nevada law still classifies non-medical marijuana as a Schedule I substance under state code. In other words: the federal floor shifted; the state statute did not. That kind of partial alignment is likely to characterize most markets for some time.
DEA Registration: Compliance Requirement or Operational Trap?
Rescheduling medical cannabis under the Controlled Substances Act triggers a set of federal requirements most state-licensed operators have never encountered. DEA registration, annual fees, detailed inventory reporting, and security protocols are standard features of pharmaceutical supply chains. They are not features of the state-regulated cannabis compliance infrastructure most dispensaries have built their operations around - think seed-to-sale tracking through METRC, state-issued compliance logs, and retailer-facing audit trails designed specifically for cannabis regulation.
Whether those two compliance architectures will align, conflict, or simply run in parallel is still undetermined. Oklahoma illustrated how messy this gets in practice: the state's narcotics bureau sent a letter to licensed medical cannabis businesses encouraging DEA registration and warning of possible sanctions, including license revocation, for non-compliance - only for the state's medical marijuana authority to clarify that it was caught off guard by the letter and that federal intent remains unclear. That is a real operational risk. An operator acting on one agency's guidance could find itself out of step with another's interpretation of the same rule.
Some operators, like Spherex Labs in Colorado, have chosen to hold off on DEA registration entirely, waiting for clearer federal direction before taking a step that carries its own compliance obligations. That's a reasonable call given the uncertainty - but it leaves businesses exposed if enforcement posture hardens before guidance arrives.
What Operators Should Be Watching Now
The DEA is scheduled to hold its first hearing on broader cannabis descheduling at the end of June. That proceeding could open the door to removing recreational cannabis from Schedule I entirely - a step that would resolve the dual-classification problem and significantly expand the federal tax and banking relief currently limited to medical operators. But regulatory proceedings move slowly, legal challenges are already filed by multiple attorneys general and advocacy groups opposing rescheduling, and the outcome of any future federal administration remains a variable no compliance team can model around.
In the meantime, several things have not changed: Transportation Security Administration rules still prohibit carrying cannabis on flights. Department of Transportation drug testing and licensing standards remain intact. Banking access for cannabis businesses - long restricted because financial institutions face federal regulatory exposure by serving Schedule I operators - has not been materially resolved by rescheduling alone. Congressional banking protections for cannabis businesses have not passed.
For dispensary operators, the honest read right now is this: the federal direction has shifted, but the operational clarity has not. The tax benefit is real, or will be once guidance lands. The compliance exposure from dual federal classifications is also real, and it's arriving faster than the answers. The businesses positioned best for what comes next are the ones maintaining clean license separation, building documentation practices that could satisfy either state or federal audit requirements, and watching the DEA hearing in June with the same attention they'd give a state legislative session - because what comes out of it may define the next several years of licensed cannabis operations in the United States.
